Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

E. Terpos, K. Ramasamy, N. Maouche, J. Minarik, I. Ntanasis-Stathopoulos, E. Katodritou, MW. Jenner, H. Plonkova, M. Gavriatopoulou, GD. Vallance, T. Pika, M. Kotsopoulou, J. Kothari, T. Jelinek, E. Kastritis, R. Aitchison, MA. Dimopoulos, A....

. 2020 ; 99 (5) : 1049-1061. [pub] 20200401

Jazyk angličtina Země Německo

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023046

Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in 155 patients who received ixazomib via early access programs in Greece, the UK, and the Czech Republic. Median age was 68 years; 17% had an Eastern Cooperative Oncology Group performance status ≥ 2; median number of prior therapies was 1 (range 1-7); 91%, 47%, and 17% had received prior bortezomib, thalidomide, and lenalidomide, respectively. Median duration of exposure to ixazomib was 9.6 months. Overall response rate was 74%, including 35% very good partial response or better (16% complete response). Median progression-free survival (PFS) was 27.6 months (27.6 and 19.9 months in patients with 1 or > 1 prior lines, respectively). IRd treatment for ≥ 6 months was associated with longer PFS (hazard ratio 0.06). Fourteen patients (9%) discontinued IRd due to adverse events/toxicity in the absence of disease progression. Peripheral neuropathy was reported in 35% of patients (3% grades 3-4). These findings support the results of the phase III TOURMALINE-MM1 trial in a broader real-world RRMM population.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023046
003      
CZ-PrNML
005      
20201214125205.0
007      
ta
008      
201125s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-020-03981-z $2 doi
035    __
$a (PubMed)32236735
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Terpos, Evangelos $u Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, 80 Vasilissis Sophias, 11528, Athens, Greece. eterpos@hotmail.com.
245    10
$a Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma / $c E. Terpos, K. Ramasamy, N. Maouche, J. Minarik, I. Ntanasis-Stathopoulos, E. Katodritou, MW. Jenner, H. Plonkova, M. Gavriatopoulou, GD. Vallance, T. Pika, M. Kotsopoulou, J. Kothari, T. Jelinek, E. Kastritis, R. Aitchison, MA. Dimopoulos, A. Zomas, R. Hajek,
520    9_
$a Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in 155 patients who received ixazomib via early access programs in Greece, the UK, and the Czech Republic. Median age was 68 years; 17% had an Eastern Cooperative Oncology Group performance status ≥ 2; median number of prior therapies was 1 (range 1-7); 91%, 47%, and 17% had received prior bortezomib, thalidomide, and lenalidomide, respectively. Median duration of exposure to ixazomib was 9.6 months. Overall response rate was 74%, including 35% very good partial response or better (16% complete response). Median progression-free survival (PFS) was 27.6 months (27.6 and 19.9 months in patients with 1 or > 1 prior lines, respectively). IRd treatment for ≥ 6 months was associated with longer PFS (hazard ratio 0.06). Fourteen patients (9%) discontinued IRd due to adverse events/toxicity in the absence of disease progression. Peripheral neuropathy was reported in 35% of patients (3% grades 3-4). These findings support the results of the phase III TOURMALINE-MM1 trial in a broader real-world RRMM population.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a sloučeniny boru $x aplikace a dávkování $x škodlivé účinky $7 D001896
650    _2
$a dexamethason $x aplikace a dávkování $x škodlivé účinky $7 D003907
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glycin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D005998
650    _2
$a lidé $7 D006801
650    _2
$a lenalidomid $x aplikace a dávkování $x škodlivé účinky $7 D000077269
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
650    _2
$a recidiva $7 D012008
650    _2
$a míra přežití $7 D015996
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Ramasamy, Karthik $u Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. NIHR BRC Blood Theme, Oxford, UK.
700    1_
$a Maouche, Nadjoua $u Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. NIHR BRC Research Education and Training Group, Oxford, UK.
700    1_
$a Minarik, Jiri $u Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Ntanasis-Stathopoulos, Ioannis $u Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, 80 Vasilissis Sophias, 11528, Athens, Greece.
700    1_
$a Katodritou, Eirini $u Department of Hematology, Theagenio Cancer Hospital, Thessaloniki, Greece.
700    1_
$a Jenner, Matthew W $u Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
700    1_
$a Plonkova, Hana $u Department of Hemato-Oncology, University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Gavriatopoulou, Maria $u Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, 80 Vasilissis Sophias, 11528, Athens, Greece.
700    1_
$a Vallance, Grant D $u Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
700    1_
$a Pika, Tomas $u Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Kotsopoulou, Maria $u Department of Hematology, Metaxa Cancer Hospital, Piraeus, Greece.
700    1_
$a Kothari, Jaimal $u Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. NIHR BRC Blood Theme, Oxford, UK.
700    1_
$a Jelinek, Tomas $u Department of Hemato-Oncology, University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Kastritis, Efstathios $u Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, 80 Vasilissis Sophias, 11528, Athens, Greece.
700    1_
$a Aitchison, Robin $u Buckinghamshire Healthcare NHS Trust, Amersham, Bucks, UK.
700    1_
$a Dimopoulos, Meletios A $u Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, 80 Vasilissis Sophias, 11528, Athens, Greece.
700    1_
$a Zomas, Athanasios $u EUCAN Medical Affairs, Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Zurich, Switzerland.
700    1_
$a Hajek, Roman $u Department of Hemato-Oncology, University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 99, č. 5 (2020), s. 1049-1061
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32236735 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214125205 $b ABA008
999    __
$a ok $b bmc $g 1595365 $s 1113722
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 99 $c 5 $d 1049-1061 $e 20200401 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace